Biologic monotherapy in the treatment of rheumatoid arthritis

Jacqueline Detert
Pascal Klaus
Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany

Abstract: Biologics, possibly in combination with a conventional disease-modifying antirheumatic drug (DMARD) – preferably methotrexate (MTX), are used in accordance with the recommendations of the international rheumatological societies. However, in clinical practice, this recommendation is often problematic, as many rheumatologists know from personal experience. The quality of life of the patient is affected mainly by drug-induced intolerances (eg, MTX). Thus, the acceptance of the patient to treatment is often so inadequate that a discontinuation of the drug is necessary. In daily practice, approximately 30% of patients with biological therapy receive no concomitant DMARD according to the register data.

Keywords: efficacy, safety, methotrexate, autoimmune disease

Introduction
Rheumatoid arthritis (RA), an autoimmune disorder, is a chronic arthritis that affects five or more joints, and 0.5%–1.0% of adults worldwide suffer from this disease.1,2 It is characterized by persistent synovitis, systemic inflammation, and development of autoantibodies (particularly to rheumatoid factor and citrullinated peptide).3,4 The goal of treatment in RA management is to achieve a remission or a very low disease activity. As a first step, the patient is treated with a conventional synthetic disease-modifying antirheumatic drug (csDMARD) therapy with or without concomitant glucocorticoid therapy recommended in order to achieve this goal.5,6 The key to success is the early initiation of therapy within the “windows of opportunity” with regular assessment of disease activity, and if necessary, adaptation of therapy in co-decision with the patient.5–7

Methotrexate (MTX) remains the standard therapy for RA, but despite the introduction of other csDMARDs, the remission rate for MTX treatment is <65%.8 Biologics affect pro-inflammatory factors (cytokines, cytokine receptors, and specific inflammatory cell types). High-cost biological treatments (biological DMARDs, bDMARDs) are usually reserved for use if csDMARDs are ineffective and contraindicated, and in cases of nonresponse, drug-induced adverse events (AEs), or bad compliance of patient (Figure 1).5–7,9

Evidence for biological monotherapy, obtained as a result of clinical trials, are often only available as an accompanying statement.10 Only few clinical studies with the primary objective to verify the efficacy and safety of monotherapy are published.11,12 The results from observational registries can provide good information about the duration of therapy. However, these registers are subject to a bias effect...
and are therefore potentially limited in the final statement on monotherapy. The analysis of the study data leads to treatment with tumor necrosis factor (TNF) inhibitors, and so far, results have shown that the concomitant MTX treatment leads to an increased effectiveness and long-term persistence.

However, future biological monotherapies will gain their clinical value and be supported by further comparative studies. Elderly patients may highlight the monotherapy as a valuable option, especially if the application of the drugs is also suitable or not contraindicated in them.

A recent and challenging need is the further optimization of therapy for achieving remission in every stage of the disease. For this review article, PubMed, MEDLINE, EMBASE, and Cochrane Library databases literature and clinical trial register were searched for clinical studies with the aim of analyzing biological monotherapy in RA. Both authors independently examined each eligible study and extracted data. Trials and research data information only in abstract format were excluded. Due to the objectives of the review, we limited ourselves to prospective, randomized clinical trials, data from registers, summaries of biologic monotherapies, and recommendation. We have tested results of reviews and recommendations.

**Use of biologic monotherapy in the treatment of RA**

Approximately 30%–33.6% of RA patients are receiving biologics as monotherapy. These data are supported by various observation registers. Most clinical studies support the higher efficacy of combination therapy of traditional csDMARDs with biological agents, while the same clinical efficacy was seen in the direct comparison of monotherapy with MTX or biologics. Data are available from biological monotherapy studies and from observational registers for abatacept (ABA), adalimumab (ADA), anakinra, certolizumab (CZP), etanercept (ETA), golimumab (GOL), infliximab (IFX), rituximab (RTX), tocilizumab (TCZ), and tofacitinib (TOF). Table 1 shows the most important data for biologics application.

### Effectiveness of biologic monotherapy vs combination therapy with csDMARDs

**Abatacept**

There are several studies on ABA in monotherapy available. In an early pilot study of ABA, a Phase II study with patients who were treated unsuccessfully with at least one DMARD, ABA monotherapy was compared to placebo ADA. There was a higher proportion of patients with American College of Rheumatology (ACR) 20 response in the treatment group with the highest ABA dosage of 10 mg/kg compared to placebo (53% vs 31%).

The ARRIVE trial was a six-month open-label study. One thousand forty-six patients after inadequate response to anti-TNF therapy for 3 months or longer and with disease activity score (DAS) 28 of 5.1 or greater were included in this study. The trial compared a wash-out phase after switching to ABA with patients switching directly. Forty-three of these patients received ABA as monotherapy; there was no placebo group. The investigators observed a slightly lower efficacy of ABA in monotherapy: the percentage of patients with a clinically meaningful improvement in DAS28 was 48.8% in the monotherapy subgroup compared to 56.1% of patients receiving combination therapy with MTX.
Table 1 Most important data for biologics use

<table>
<thead>
<tr>
<th>Substance</th>
<th>Approval for</th>
<th>Application form</th>
<th>Application interval</th>
<th>Main effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abatacept</td>
<td>Plus MTX</td>
<td>iv</td>
<td>Every other 4 weeks</td>
<td>Inhibition of the T-cell costimulation</td>
</tr>
<tr>
<td>Adalimumab</td>
<td>Plus MTX and monotherapy&lt;sup&gt;a&lt;/sup&gt;</td>
<td>sc</td>
<td>Every other 2 weeks</td>
<td>TNF inhibition</td>
</tr>
<tr>
<td>Anakinra</td>
<td>Plus MTX&lt;sup&gt;a&lt;/sup&gt;</td>
<td>sc</td>
<td>Daily</td>
<td>IL-1 inhibition</td>
</tr>
<tr>
<td>Certolizumab</td>
<td>Monotherapy</td>
<td>sc</td>
<td>Every other 2 weeks</td>
<td>TNF inhibition</td>
</tr>
<tr>
<td>Etanercept</td>
<td>Plus MTX and monotherapy&lt;sup&gt;a&lt;/sup&gt;</td>
<td>sc</td>
<td>Weekly</td>
<td>TNF inhibition</td>
</tr>
<tr>
<td>Golimumab</td>
<td>Plus MTX</td>
<td>sc</td>
<td>Every other 4 weeks</td>
<td>TNF inhibition</td>
</tr>
<tr>
<td>Infliximab</td>
<td>Plus MTX</td>
<td>iv</td>
<td>0 week, 2 weeks, 6 weeks, and 8 weeks</td>
<td>TNF inhibition</td>
</tr>
<tr>
<td>Rituximab</td>
<td>Plus MTX</td>
<td>iv</td>
<td>Weeks 0 and 2</td>
<td>B-cell depletion</td>
</tr>
<tr>
<td>Tocilizumab</td>
<td>Monotherapy</td>
<td>iv</td>
<td>Every other 4 weeks</td>
<td>IL-6 inhibition</td>
</tr>
<tr>
<td>CP-690550 tofacitinib</td>
<td>Monotherapy</td>
<td>Oral</td>
<td>Daily</td>
<td>JAK3 inhibition</td>
</tr>
</tbody>
</table>

Notes: <sup>a</sup>In cases of contraindications or adverse events, they can be used as monotherapy; <sup>b</sup>in Europe.

Abbreviations: iv, intravenously; sc, subcutaneously; MTX, methotrexate; TNF, tumor necrosis factor; IL, interleukin; JAK3, Janus kinase inhibitor 3.

The ACCOMPANY trial is an ongoing randomized open-label study comparing 125 mg weekly ABA monotherapy with or without MTX. Adalimumab is administered subcutaneously. The short-time phase included 100 patients and lasted for 4 months. Patients then entered the ongoing long-term extension phase where MTX could be added at the investigator’s discretion. During the short-term phase, mean DAS28 improvement was actually numerically better in the monotherapy group (changes were −1.67 for combination and −1.94 for monotherapy). To verify the effectiveness and to predict effectiveness factors of ABA in real life, a prospective observational study was performed (the French “Orencia and Rheumatoid Arthritis” [ORA] prospective registry) with 1,003 RA patients. Seven hundred and seventy-three patients had already fulfilled the 6-month follow-up visit. Efficacy was determined by the European League Against Rheumatism (EULAR) response. In addition, the rheumatological antibodies (rheumatoid factor, anti-cyclic citrullinated peptide antibody [anti-CCP]) of the patients were evaluated. Real-life efficacy of ABA in the registry was similar as that reported in clinical trials. Anti-CCP positivity was associated with a better response to ABA, independently from DAS28.

Adalimumab

ADA is licensed for monotherapy when administration of MTX is not possible. In a double-blind, Phase III study, 544 patients with previous failure of DMARDs were randomized to receive one of the four different dosages of ADA or placebo. The investigators demonstrated that all dosages were superior to placebo. In the PREMIER trial, however, where 799 patients with early RA who were MTX naïve received MTX, ADA, or MTX plus ADA for 2 years, there was a twofold higher percentage of patients with combination therapy achieving remission compared to MTX or ADA alone. When comparing only the two monotherapy groups alone, there was a lower radiographic progression in ADA compared to MTX.

The open-label extension of the PREMIER trial was conducted in the combination of ADA with slightly less MTX as the lack of efficacy was canceled in ADA monotherapy. The prevention of radiological progression is more efficient in patients who were randomized to ADA plus MTX (change in total modified Sharp score =4.0, 8.8, and 11.0 at year 10 for the initial ADA plus MTX, ADA, and MTX arms, respectively). The combination therapy appears far more effective than monotherapy in the results. If possible, the combination therapy with MTX over biological monotherapy should be preferred, and the combination therapy should appear for approval.

Anakinra

In the European monotherapy study, 43% of patients receiving 150 mg/day antinuclear antibody (ANA) achieved a 20% response according to the ACR20 criteria, compared to 27% in the placebo group. The clinically meaningful improvements in the Health Assessment Questionnaire scores were observed. The mean change in the total modified Sharp score of patients who completed treatment with ANA was significantly less than in the patients who received placebo (2.21 vs 3.81). A treatment effect was not observed in the low-dose monotherapy study.

Certolizumab

CZP is also licensed for monotherapy when administration of MTX is not possible. In the FAST4WARD trial, 220 patients who have failed one or more DMARDs were randomized to receive CZP monotherapy or placebo for 6 months. The proportion of patients who achieved an ACR20 response
was greater in the monotherapy group than in the placebo group. The REALISTIC trial was a Phase IIIb study with 1,063 patients who have failed at least one DMARD and were randomized 4:1 to receive CZP or placebo in addition to their current therapy. This included approximately 20% of patients without concomitant DMARD use. There was a significant improvement in the ACR20 response regardless of concomitant csDMARD use.

**Etanercept**

In the ETA trial, 632 patients with early RA were randomized to receive 10 mg or 25 mg of ETA in monotherapy weekly or oral MTX for 12 months. In the group of patients receiving the higher dose of ETA, there was a more rapid improvement, and higher percentage was having ACR20, 50, and 70 improvement during the first 6 months compared to MTX. After 12 months, there was no statistical difference between the two groups regarding ACR responses. However, the overall increase in bone erosion scores was lower in the ETA group than in the MTX group, both after 6 months and after 12 months. Patients from TEMPO (n=682) and RADIUS II (n=4341) trials who received ETA monotherapy showed similar remission rates in Clinical Disease Activity Index (CDAI) at year 3 (39% and 35%, respectively). MTX- and ETA-treated patients showed remission rates of 54% and 36%, respectively. More patients with lower baseline CDAI scores achieved remission than those with higher scores.

In the COMET trial, patients with early RA (n=542) received either ETA plus MTX or MTX alone for 1 year. After that time, patients with combination therapy were randomized to continue on combination therapy or receive ETA in monotherapy. Patients from the original MTX monotherapy group were randomized to continue MTX monotherapy or to receive additional ETA. Removal of MTX from patients receiving combination therapy resulted in deteriorated clinical and radiographic results compared to patients who continued combination therapy. There were also several studies with patients who previously had an inadequate response to MTX. In the open-label ADORE trial, ETA added to patients’ baseline MTX was compared to switching to ETA monotherapy. Overall, there was a significant clinical improvement from baseline in both groups, and no significant differences between the two groups were observed. In the JESMR trial, ETA plus MTX was significantly superior to ETA alone regarding both clinical response and radiographic progression. The CAMEO trial was another study where patients were treated with combination therapy of ETA plus MTX and then randomized to continue combination therapy or switch to ETA monotherapy. Patients in the ETA monotherapy group deteriorated compared to combination therapy. This was especially the case for patients who were not in remission or having low disease activity at the time of randomization. Data from the Swedish biologics registry showed that patients had better adherence to therapy when they received ETA combined with MTX as opposed to ETA monotherapy. This was also the case for IFX monotherapy. Reasons for withdrawal were both lack of efficacy and the occurrence of AEs. The authors attributed this to the formation of antidrug antibodies (ADrAb).

**Golimumab**

In the GO-BEFORE trial, 637 MTX-naïve patients were randomized to receive GOL plus MTX or GOL or MTX alone. According to the intention-to-treat population, combination therapy was not superior to MTX. There was a significant advantage of GOL and MTX compared to either substance alone than three untreated patients in the post hoc analysis were excluded. There were no significant differences between GOL or MTX monotherapy. In the GO-FORWARD study, patients with insufficient response to MTX were randomized to receive GOL plus MTX or either drug alone. There was a better clinical response in the combination group compared to GOL or MTX alone. Of note, GOL monotherapy was significantly superior to MTX monotherapy regarding ACR20 response.

**Infliximab**

There are few studies that demonstrate the efficacy of IFX monotherapy, but there are no trials comparing IFX monotherapy to MTX. One reason for this may be the fact that it was recognized relatively quickly that infusion-related side effects in combination with MTX could be reduced. Nevertheless, an evaluation of an observation register shows that in the case of MTX contraindications, IFX monotherapy provides similar efficacy as ETA. In a retrospective cohort study from the USA using Medicare data with over 10,500 patients using a TNF inhibitor in monotherapy, patients with IFX alone were 1.8 times more likely to discontinue medication compared to patients using combination therapy.
with MTX. Patients with other TNF inhibitors were 1.4 times more likely to discontinue therapy when using monotherapy. The authors postulated that this was mostly due to the immunogenic potential of IFX.16

**Rituximab**

In an open-label Phase II study, patients with inadequate response to MTX were randomized to receive RTX plus MTX or cyclophosphamide or MTX or RTX in monotherapy. RTX plus MTX was superior to RTX or MTX alone according to, for example, ACR50 response. RTX monotherapy was also superior to MTX monotherapy, and the difference in response rates between RTX alone and MTX alone was more pronounced than between combination therapy and RTX alone.54 In a small open-label study, 40 patients were randomized to receive a single infusion of RTX plus MTX or RTX alone. Again, there were better ACR response rates in the combination group.55 There was also a trend suggesting earlier repopulation of B cells in the monotherapy group which could indicate shorter duration of clinical response.

**Tofacitinib**

TOF is not a biologic but a Janus kinase inhibitor belonging to the novel group of oral small molecules for the treatment of RA. TOF monotherapy has been compared to placebo in several studies.60 In the ORAL Solo trial, 611 patients with inadequate response to bDMARDS or csDMARDS were randomized to receive one of the three different dosing regimens or placebo. TOF was significantly superior to placebo.61 These findings were confirmed in the ORAL Start trial with 958 MTX-naïve patients. To date, there are no completed studies available comparing TOF monotherapy to TOF plus MTX.34 However, the ORAL STRATEGY trial is currently recruiting patients with inadequate MTX response to compare TOF alone with TOF plus MTX and ADA plus MTX (NCT02187055).

**Safety of biologic monotherapy vs combination therapy with csDMARDs**

**General safety considerations**

According to the available data from the large randomized controlled clinical trials, there is no added safety risk when combining biologics with csDMARDs. This was confirmed by a recent meta-analysis.62 Vice versa, biologics in monotherapy do not have a lower safety risk compared to combination therapy. Typical safety concerns associated with bDMARD and csDMARD therapy are infections including severe respiratory tract infections, reactivation of tuberculosis and hepatitis B, nonmelanoma skin malignancies, injection-site reactions, and zytopenias.63 For example, for ABA, there was a comparable rate of AEs and severe AEs (SAEs) in the ARRIVE study both in the monotherapy and in the combination therapy groups.10 In the ACCOMANY trial, there was a slightly higher rate of SAEs in the monotherapy group and a slightly higher rate of AEs in the combination therapy group.21 For ADA, there was a comparable rate of AEs and SAEs in the PREMIER trial in all three groups (MTX, ADA, or MTX plus ADA), but serious infections were more frequent in the combination therapy group (2.9%) compared to ADA alone (0.7%; \( P<0.05 \)).22 In the ERA trial, there was a lower overall incidence of AEs and fewer infections in the ETA monotherapy group than in the MTX monotherapy group.45 In the TEMPO trial, there were also a similar number of AEs and infections in patients receiving ETA or MTX in monotherapy or the combination of both.64,65 Also, in the COMET trial, there was no additional
safety risk in patients receiving combination therapy. For GOL, there was a slightly higher overall incidence of AEs in the two combination groups compared to either substance in monotherapy in the GO-BEFORE trial. Similar rates of AEs were observed in both RTX monotherapy and combination therapy trials. The ADACTA trial showed that TOF has a safety profile that is similar to bDMARDs. In addition, elevated low-density and high-density lipoprotein cholesterol levels and reduced neutrophil counts can occur. There has been a slightly higher rate of overall AEs in the TOF plus MTX group compared to MTX alone.

Antidrug antibodies

The development of ADrAb has been associated with bDMARD as they present an immunogenic target for the immune system. The formation of ADrAb has been observed for most biologics. Low titers are thought not to influence the efficacy of the drug, whereas high titers may impair the efficacy by neutralizing the drug. Concomitant administration of other immunosuppressive drugs such as MTX has been shown to reduce the incidence of ADrAb. In the ACCOMPANY trial for ABA, transient immunogenicity with detection of ADrAb was seen in approximately 4% of patients regardless of concomitant MTX use. After 4 months, however, anti-ABA antibodies were detected in none of the patients. For ADA, MTX has been shown to reduce immunogenicity in a dose-dependent manner. For CZP, the formation of ADrAb has been found in approximately 12% of patients, with unknown clinical significance. Forty-four percent of RA patients were positive for anti-IFN after 6 months of treatment. Antibodies against TCZ have been found in only a small number of patients, and treatment efficacy was maintained even in the presence of those antibodies. The formation of ADrAb was not affected by concomitant use of MTX in the ACT-RAY trial. The impact of baseline ANA status and use of MTX play a major role in the development of IFX-related infusion reactions in patients. The risk of an allergic infusion reaction is particularly high if the ANA status in the patient is positive at baseline and if IFX is administered as monotherapy.

Comparative effectiveness of biologic monotherapies: the ADACTA trial

The next step is the conversion to other csDMARDs if the patient cannot tolerate MTX. However, if signs of a high disease activity and if already radiologically demonstrable erosions are present, the patient can be directly switched to monotherapy with a biologic. According to the data from ADACTA trial, TCZ appears to be suitable for first-line biologic therapy. In a head-to-head comparison, it was found to be superior to ADA monotherapy.

Patients from ADACTA trial were randomly assigned to receive 8 mg TCZ per kilogram bodyweight intravenously every 4 weeks plus placebo subcutaneously every 2 weeks or 40 mg ADA subcutaneously every 2 weeks plus placebo intravenously every 4 weeks for 24 weeks. Three hundred and twenty-six patients enrolled in this trial. The mean change from baseline in DAS28 was significantly greater at week 24 in the TCZ group than in the ADA group (difference –1.5, 95% confidence interval –1.8 to –1.1; \(P<0.0001\)). The recommendations for TCZ monotherapy are supported by the results of the ACT-RAY study. They showed that TCZ as monotherapy and in combination with MTX shows a similar rate of DAS28 remission at week 24 (34.8% vs 40.4%; \(P=0.21\)). In addition, the patients showed a similar reduction in the number of swollen joints and tenderness of joints at weeks 24 and 52.

The results of the safety analysis in the ADACTA trial showed only marginal differences. In the ADA group (16 [10%] of 162), there appeared slightly less serious adverse effects than in the TCZ group (19 [12%] of 162). The TCZ group had more patients with increased low-density lipoprotein cholesterol, increased alanine aminotransferase concentrations, and reduced platelet and neutrophil counts than the ADA group. But what we do not know is how the monotherapy with TCZ could be compared to the combination of MTX and ADA. The ADACTA trial does not provide a comparison with standard therapy. The results therefore provide no justification for an increased indication of monotherapy.

Conclusion and future research perspectives

In general, biologics enrich and change the RA therapy. This applies to all biologics. TCZ shows good efficacy and tolerability. Of course, patients treated with TCZ do not respond or show any side effects as with other biologics. TCZ should also be used in monotherapy if the treatment is established for it. In addition, there is the possibility that an accompanying csDMARD subsequently could be discontinued if a good response to therapy reduces the burden on the patient. This procedure must be documented in future with study data, as well as comparative studies with other biologics as monotherapy. As the first choice in the treatment of RA patients csDMARDs should be preferred,
because a sufficiency treatment is possible for most patients and treatment with biologics is very costly. Also, the previous long-term data show that especially, combination treatments (csDMARD with bDMARD) are often more effective than monotherapy alone.

Disclosure

The authors report no conflicts of interest in this work.

References


